Skip to contentClarengateINTELLIGENCE
Companies/12359622

Mint Holdco UK Limited

Private Limited Company · Fareham

ActiveUnited KingdomIncorporated 2019Private Limited Company
Register Ask analyst

Financial position

Accounts to 2025-12-31 · EUR · Group accounts

Net assets
—
Cash
EUR 14,209,000
Turnover
EUR 115,325,000
Profit / loss
—
Current assets
EUR 52,768,000
Creditors < 1 year
—
Equity
—
Average employees
747

Balance-sheet trend

EUR · consolidated

Financial statements

Selected figures from the best-ranked available filing for each period. Missing values remain unknown.

2 periods

Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts

Reported figures2025-12-31Group · AI-read2024-12-31Group · AI-read
Assets
Fixed assetsEUR 174,850,000EUR 133,256,000
Intangible assetsEUR 18,552,000EUR 17,654,000
Property, plant & equipmentEUR 121,383,000EUR 71,516,000
Current assetsEUR 52,768,000EUR 31,221,000
Cash at bankEUR 14,209,000EUR 6,203,000
DebtorsEUR 16,205,000EUR 11,008,000
StockEUR 7,323,000EUR 5,887,000
Profit & loss
TurnoverEUR 115,325,000EUR 78,517,000
Other operating incomeEUR 55,511,000EUR 2,666,000
Cash flow
Cash from operationsEUR 14,738,000EUR 12,179,000
Capital expenditureEUR 8,201,000EUR 5,278,000
People & pay
Average employees747538
Staff costsEUR 65,082,000EUR 40,431,000
Wages & salariesEUR 50,219,000EUR 30,265,000
Social security costsEUR 8,551,000EUR 6,600,000
Pension costsEUR 61,000EUR 54,000
Source evidenceView filing View filing

From the accounts

What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.

Auditor
Ernst & Young LLP
Immediate parent
Mint Topco UK Limited
Ultimate controlling party
GHO Capital Partners LLP
Accounts
IFRS
Approved
2026-08-26, signed by Alan Mackay
Turnover by segment (20)
  • Pharma: 55.401 (000s) (2025-12-31)
  • Biotech: 52.601 (000s) (2025-12-31)
  • Other: 7.323 (000s) (2025-12-31)
  • Pharma: 23.070 (000s) (2024-12-31)
  • Biotech: 50.281 (000s) (2024-12-31)
  • Other: 5.166 (000s) (2024-12-31)
  • Asia: 4.922 (000s) (2025-12-31)
  • Eastern Europe: 808 (000s) (2025-12-31)
  • Northern Europe: 15.710 (000s) (2025-12-31)
  • Southern Europe: 6.780 (000s) (2025-12-31)
  • Western Europe: 46.940 (000s) (2025-12-31)
  • North America: 39.219 (000s) (2025-12-31)
  • Oceania: 946 (000s) (2025-12-31)
  • Asia: 6.166 (000s) (2024-12-31)
  • Eastern Europe: 1.568 (000s) (2024-12-31)
  • Northern Europe: 13.346 (000s) (2024-12-31)
  • Southern Europe: 4.527 (000s) (2024-12-31)
  • Western Europe: 31.180 (000s) (2024-12-31)
  • North America: 19.798 (000s) (2024-12-31)
  • Oceania: 1.932 (000s) (2024-12-31)
Related parties (6)
  • Ardena Mint BV · subsidiary · intercompany receivable · 217 Keur (000s)
  • Ardena Mint BV · subsidiary · intercompany receivable · 116 Keur (000s)
  • Ardena Bioanalysis BV · subsidiary · intercompany receivable · 139 Keur (000s)
  • Ardena Bioanalysis BV · subsidiary · intercompany receivable · 18 Keur (000s)
  • Mint Topco UK Ltd · immediate parent company · current account receivable · 21 Keur (000s)
  • Mint Topco UK Ltd · immediate parent company · current account receivable · 21 Keur (000s)
Borrowings (4)
  • External loan · 89.431 Keur (000s) · Bullet-loan with maturity date December 31, 2026
  • Revolving facility · 2.000 Keur (000s) · Revolving facility
  • Lease debt · 16.304 Keur (000s)
  • Factoring with recourse · 624 Keur (000s)
Share classes (1)
  • 171.584.022 ordinary of 0,01 Eur
Events after the year end (3)
  • Subsequent to 31 December 2025, the Group completed the sale of 100% of the shares of Ardena Södertälje AB to Nanologica AB; the transaction was signed and closed on January 29, 2026.
  • On April 1, 2026 the Group acquired Pharmatel-Immo BV, being the entity that owns the building used for the operations of Ardena Gent NV.
  • Subsequent to the reporting date, the Group successfully refinanced its existing debt facilities with its current lending partners.

Secured borrowing

Registered charges, lenders and security interests.

Charges and related records

4 outstanding charges
Fixed · created 2024-04-19
—
Outstanding
Fixed · created 2024-02-08
—
Outstanding
Fixed · created 2023-08-14
—
Outstanding
—
Outstanding